CRACR2A and neoplasm: Another study identified the exact same region of CRACR2A (listed as EFCAB4B) as the top‐ranking DMR hypermethylated in breast cancer patients resistant to endocrine therapy, with a strong negative correlation with gene expression, and hypothesise that the observed methylation change may be regulating immune/inflammatory alterations in the tumour microenvironment.49